-
Crisaborole
Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika) Crisaborole ʻO ka Dermatitis Atopic a me ka Eczema Pfizer -
Etelcacetide
Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika) Etelcacetide Hyperparathyroidism lua (HPT) Amgen -
Abemaciclib
Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika) Abemaciclib ʻO ka maʻi maʻi ʻai, mālama ʻana i ka maʻi maʻi prostate Eli Lily Dek.15,2029 -
ʻO Deucracitinib
Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika) ʻO Deucracitinib Anti plaque psoriasis ʻO Bristol-Myers Squibb Company Nov.07,2033 -
Apremilast
Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika) Apremilast psoriatic arthritis Celgene -
Remdesivir
Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika) Remdesivir Nā Antivirus(Ebola, Covid-19) Gileada -
Pomalidomide
Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika) Pomalidomide Laau oncology Celgene -
Nirmatrelvir
Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika) Nirmatrelvir ʻO ka 3C-Like Protease (3CLPRO) ka mea pale a me ka SARS-Cov-2 Mpro kaohi. -
Eltrombopag
Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika) Eltrombopag ITP & Aplastic anemia Novartis & GSK Mei. 20, 2023 -
ʻO Ruxolitinib
Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika) ʻO Ruxolitinib Myelofibrosis Novartis Iulai 6, 2024 -
Crisaborole
Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika) Crisaborole ʻO ka Dermatitis Atopic a me ka Eczema Pfizer Iune 11, 2026